

For professional clients only – not for distribution to retail clients.

Fund Aim

The fund aims to provide long-term capital growth through investment primarily in Continental European equities.

TOP 10 HOLDINGS

1.	Nestlé	7.1%
2.	Roche	7.0%
3.	Novartis	6.3%
4.	Tethys Oil	3.8%
5.	Tokmanni	3.6%
6.	Raiffeisen	3.4%
7.	Mycronic	3.4%
8.	Novo Nordisk	3.3%
9.	BW Offshore	2.8%
10.	AST Groupe	2.8%

PERFORMANCE

	Class B EUR	STOXX Europe 600 ex UK
3 months	0.4%	1.9%
6 months	-0.1%	2.4%
12 months	0.7%	4.5%
Since launch (11 Sept. 2015)	26.1%	18.7%

	Class B EUR	STOXX Europe 600 ex UK
2018 YTD	-1.9%	1.3%
2017	13.9%	11.6%
2016	8.6%	2.4%
2015 (from 11 Sept.)	4.0%	2.6%

Commentary

In August the Comeragh European Growth Fund fell 1.9% vs. the decline of 1.6% registered by the Euro STOXX 600 ex UK index.


The month saw continued strong performance from US markets, punctuated by both the S&P 500 and NASDAQ indices hitting record highs in four consecutive sessions. Such ebullience, however, was not to be found anywhere else. European markets fell – and in a sign of increasing “risk-off” appetite, emerging markets fared much worse. The investment cycle of the past nine years has been characterised by US tech/growth leadership in an environment of disinflation and falling interest rates. Apple and Amazon, emblematic of this theme, have reached \$1 trillion valuations against what is beginning to look like an emerging market rout. The extent of the divergence between US equity and that of the world, alongside a decline in market breadth, suggests that the cycle is entering a climactic phase. This gives us continued cause for caution and we retain an elevated cash position and a large overweight in the defensive, dollar earning pharmaceutical sector.

The best performing stock this month has been BW Offshore, a provider of floating production systems to the oil and gas industry. Following a sustained period of stronger oil prices, activity has been improving – a trend that


looks set to continue. The worst performing stock was Implenia, the Swiss construction company, which reported weak margins and earnings despite strong revenue growth. Whilst disappointing, the stock remains cheap and the balance sheet rock solid, with net cash of nearly 3x EBITDA.

The Fund trades on a P/E ratio of 12.8x, a substantial discount to the market on 15.8x. It is notable that despite this, the quality of the portfolio is significantly higher than that of the market, with a return on equity of 19.1% vs. the market on 16.6%. Whilst market momentum may currently favour high-multiple growth stocks – where in many case valuation multiples have continued to expand – we are confident that this provides an excellent platform for outperformance looking ahead.

Sector Allocation



Country Allocation



Risk Overview

	FUND	INDEX
P/E	12.8	15.8
EV/EBITDA	7.1	9.0
Div Yield	3.6%	3.6%
ROE	19.1%	16.6%
3m EPS Revs	3.0%	2.5%
Net Debt / EBITDA	0.68	0.86
Sharpe Ratio	-0.23	
Beta (3m)	0.71	

Fund Facts

Fund Status	Sub-fund of a Dublin-domiciled UCITS ICAV, authorised and regulated by the Central Bank of Ireland. Recognised in the UK by the Financial Conduct Authority
Sector	Europe ex UK
Benchmark Index	STOXX Europe 600 ex UK
Fund Size	€69.0m
Fund Launch Date	11 th September 2015

Class	ISIN	SEDOL	Distribution Type	Annual Management Fee	Initial Minimum Subscription
Class A EUR	IE00BYN38431	BYN3843	Income	0.60%	€100,000
Class A GBP Hedged	IE00BYN38985	BYN3898	Income	0.60%	£100,000
Class B EUR	IE00BYN38M12	BYN38M1	Accumulation	0.60%	€100,000
Class B GBP Hedged	IE00BYN38Q59	BYN38Q5	Accumulation	0.60%	£100,000
Class C EUR	IE00BYN38Y34	BYN38Y3	Income	0.75%	€500
Class C GBP Hedged	IE00BYN39629	BYN3962	Income	0.75%	£500
Class D EUR	IE00BYN39B71	BYN39B7	Accumulation	0.75%	€500
Class D GBP Hedged	IE00BYN39C88	BYN39C8	Accumulation	0.75%	£500

Further Information

Email: info@comeraghcapital.com

Website: www.comeraghcapital.com

Telephone: +44 (0) 207 381 5022

Dealing:

- Daily dealing (except Irish public holidays)
- 11.00 dealing cut-off (forward pricing)
- 17.00 valuation point
- CACEIS Ireland
 - + 353 (0)1 672 1631
 - One Custom House Plaza, IFSC, Dublin D01 C2C5, Ireland

Risk Warning

The value of investments and the income from them can go down as well as up and investors may not receive back the original amount invested. Past performance is not an indicator of future performance. Exchange rates may cause the value of the underlying overseas investments to go down as well as up. Investment in smaller companies may involve a higher degree of risk as markets are usually more sensitive to price movements.

Please read the Risk Section of the Fund's Prospectus and Key Investor Information Document (KIID) for a fuller description of the risks prior to investing. Comeragh Capital LLP and its affiliates and/or their officers, partners and employees may own or have positions in the fund and/or any investment mentioned herein. The factsheet does not represent an invitation to invest in the Fund. Subscriptions must be made in conjunction with the KIID and Prospectus, copies of which can be obtained free of charge in English at www.comeraghcapital.com. Comeragh Capital LLP acts as investment manager and promoter to Comeragh Funds ICAV.